DOP2002000347A - PHARMACEUTICAL COMPOSITIONS. - Google Patents
PHARMACEUTICAL COMPOSITIONS.Info
- Publication number
- DOP2002000347A DOP2002000347A DO2002000347A DO2002000347A DOP2002000347A DO P2002000347 A DOP2002000347 A DO P2002000347A DO 2002000347 A DO2002000347 A DO 2002000347A DO 2002000347 A DO2002000347 A DO 2002000347A DO P2002000347 A DOP2002000347 A DO P2002000347A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pharmaceutical compositions
- compositions
- ldl5
- pravastatin
- cholesterol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona métodos y composiciones farmacéuticas para reducir los niveles de LDL5 colesterol en mamíferos, que comprende la administración de una cantidad terapéuticamente efectiva de más de 40 mg, una vez al día de pravastatina, o una sal o éster del mismo farmacéuticamente aceptable, a un mamífero en necesidad de tal tratamiento.The present invention provides pharmaceutical methods and compositions for reducing levels of LDL5 cholesterol in mammals, comprising the administration of a therapeutically effective amount of more than 40 mg, once a day of pravastatin, or a pharmaceutically acceptable salt or ester thereof, to a mammal in need of such treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DO2002000347A DOP2002000347A (en) | 2002-02-26 | 2002-02-26 | PHARMACEUTICAL COMPOSITIONS. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DO2002000347A DOP2002000347A (en) | 2002-02-26 | 2002-02-26 | PHARMACEUTICAL COMPOSITIONS. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2002000347A true DOP2002000347A (en) | 2002-11-30 |
Family
ID=44261063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2002000347A DOP2002000347A (en) | 2002-02-26 | 2002-02-26 | PHARMACEUTICAL COMPOSITIONS. |
Country Status (1)
| Country | Link |
|---|---|
| DO (1) | DOP2002000347A (en) |
-
2002
- 2002-02-26 DO DO2002000347A patent/DOP2002000347A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251419A1 (en) | NANOPARTICULATED COMPOSITIONS OF EPLERENONA | |
| ES2916649T1 (en) | Compositions and uses for the treatment of multiple sclerosis | |
| UY26635A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| NO20025601D0 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
| BR0115109A (en) | Therapeutic agents and methods of their use for angiogenesis modulation | |
| SV2002000036A (en) | OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA | |
| ES2721899T3 (en) | Pharmaceutical compositions comprising fentanyl for intranasal administration | |
| CA2459470A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use | |
| AR046036A1 (en) | RISEDRONATE COMPOSITIONS AND METHODS FOR USE | |
| CO5570661A2 (en) | COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS | |
| IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
| EP1962843A4 (en) | USE OF PARP-1 INHIBITORS | |
| ECSP066878A (en) | [HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - (4-BROMO-3-METHYL-5-PROPOXI-THIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE TRIPTASE | |
| CO5200850A1 (en) | PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION | |
| AR018505A1 (en) | ANTIHISTAMINAL PHARMACEUTICAL COMPOSITION WITH AN INHIBITOR OF P-GLYCOPROTEIN AND THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF MEDICINES TO INCREASE THE BIODISPONIBILITY OF SUCH ANTIHISTAMINAL. | |
| Lee et al. | Prevention of NSAID-associated gastroduodenal injury in healthy volunteers-a randomized, double-blind, multicenter study comparing DA-9601 with misoprostol | |
| CO5060499A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGIC REFLECTION DISEASE | |
| CO5210869A1 (en) | A SYNERGETIC COMBINATION: GABAPENTINA AND PREGABALINA | |
| AR039162A1 (en) | VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION | |
| UY30557A1 (en) | TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS | |
| AR033424A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| AR041028A1 (en) | BETA INHIBITOR PROFARMACO-LACTAMASA | |
| ATE350064T1 (en) | PHARMACEUTICAL COMPOSITIONS OF RAPAMYCINES | |
| ES2186153T3 (en) | SULFATE 5-ALFA-PREGNAN-3-BETA-OL-20-ONA FOR THE TREATMENT OF TUMORS AND CNS DISORDERS. |